knowledge -WSS

knowledge

author：entertainment 2025-10-02 15:43:23 - browse：4

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Tuberculosis patients need more than just free medication

WSS

Brain MRIs reveal impact of 'toxic stress' on Black children

Most antidepressants don't work on kids, teens, study finds

Welsh Carson private equity firm escapes from FTC antitrust case

Doctors are clamoring for more clarity on Paxlovid prescribing

Slovenia has suffered its worst

Crowdfunding for medical bills sidesteps core problem, author says

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Flash flood warnings continue for parts of Missouri, Illinois

Drug repurposing or repositioning? The language matters

Class action alleges UnitedHealth concealed DOJ probe

Walensky prepares to leave CDC — and Congress — behind

The creative science of coining drug names

Jerome Adams on the need for new antivirals for Covid

Crowdfunding for medical bills sidesteps core problem, author says

Dobbs anniversary: the lost opportunity of abortion as health care

HHS's proposed rule does nothing to address the climate crisis

hotspot

The effects of a landmark ruling on DNA ownership are becoming clearer

As billionaires fund anti

Election results set back Medicaid expansion plans

BIO to announce reorganization, senior leaders expected to depart

Sage considers ways to reduce costs following FDA rejection

Trump used to be more articulate. What could explain the change?

leisure time

focus

focus

knowledge